Mood Stabilizers: How They Work, What to Expect & How to Stay Safe

Lithium has been in clinical use for over 70 years and remains, in most evidence reviews, the most effective treatment for bipolar disorder. Its mechanisms are multiple and not fully understood: it inhibits glycogen synthase kinase-3β (GSK-3β), a key enzyme in cell signaling pathways involved in neuronal survival; it depletes inositol, affecting phosphoinositide signaling; and it has neuroprotective effects including increased gray matter volume — lithium is one of the few psychiatric medications that actually changes brain structure in a measurable and apparently beneficial way.

FDA approvals: acute mania, and maintenance treatment of bipolar disorder. But lithium has a uniquely important property beyond symptom management: it is the only psychiatric medication with robust evidence for suicide-specific mortality reduction. Meta-analyses consistently show approximately 60% lower suicide rates in patients on long-term lithium compared to those who discontinued. For patients with bipolar disorder and significant suicidality, this is a clinically decisive consideration.

Therapeutic Index and Monitoring

Lithium has a narrow therapeutic index: the target serum level for acute mania is typically 0.8–1.2 mEq/L; for maintenance, 0.6–0.8 mEq/L is often used to balance efficacy with long-term tolerability. Levels must be checked 12 hours after the last dose, consistently. Monitoring at baseline and every 6 months includes: serum lithium levels, TSH (thyroid), and creatinine (kidney function).

Signs of Lithium Toxicity

Lithium toxicity is a medical emergency. The progression is predictable:

• Early (1.5–2.0 mEq/L): coarse tremor (distinct from the fine tremor of therapeutic levels), nausea, diarrhea, lethargy, slurred speech
• Moderate (2.0–2.5 mEq/L): confusion, disorientation, ataxia (unsteady gait), muscle twitching, increased deep tendon reflexes
• Severe (>2.5 mEq/L): seizures, cardiac arrhythmias, impaired consciousness, coma — requires emergency medical care

Any signs of toxicity are an indication to hold lithium and check a level immediately.

Drug Interactions That Raise Lithium Levels

Lithium is excreted almost entirely by the kidneys. Anything that reduces renal clearance raises lithium levels:

• NSAIDs (ibuprofen, naproxen) — reduce renal prostaglandin synthesis, decreasing lithium clearance. Common OTC drugs — patients must know this.
• ACE inhibitors and ARBs — commonly prescribed for hypertension; can raise lithium levels 20–50%
• Thiazide diuretics — sodium depletion prompts the kidney to reabsorb more lithium alongside sodium

Long-Term Considerations

Long-term lithium use carries specific risk considerations:

• Hypothyroidism: occurs in 20–40% of patients on long-term lithium; usually manageable with levothyroxine
• Nephrogenic diabetes insipidus: lithium blocks vasopressin (ADH) receptors in the kidney, impairing water concentration — produces polydipsia and polyuria. Amiloride is often used to manage this.
• Nephrotoxicity: the long-term kidney effects of lithium are controversial. Most current data suggest that maintaining the lowest effective level minimizes risk. Regular creatinine monitoring is essential; if GFR declines, reassessment of lithium necessity is warranted.
• Pregnancy: the Ebstein's anomaly risk from first-trimester lithium exposure has been revised substantially downward from older estimates. Current data suggest approximately 0.6% absolute risk (versus 0.05% baseline) — a relative increase but a small absolute risk. The decision requires individualized risk-benefit analysis for each pregnancy.

Managing Tremor and Dehydration Risk

Fine tremor at therapeutic levels is common and does not indicate toxicity. Low-dose propranolol (10–20mg) effectively manages it for most patients. The summer and exercise dehydration risk is real and underappreciated: sweating and restricted sodium intake (common in hot weather or with exercise) reduce renal lithium clearance, raising blood levels. Patients need concrete instructions about hydration, sodium intake, and when to check levels if they are sweating heavily or ill.

Valproate (brand name Depakote as divalproex sodium) has FDA approval for acute mania and is particularly useful in clinical scenarios where lithium is less effective or appropriate: mixed states (simultaneous manic and depressive features), rapid cycling (four or more episodes per year), and mania with comorbid substance use disorder. The mechanism involves potentiation of GABA-A receptors and sodium channel blockade.

Monitoring and Side Effects

Target serum level: 50–125 mcg/mL for bipolar mania. Baseline labs include LFTs (liver function) and CBC (complete blood count), repeated periodically. Side effects include weight gain, hair loss (selenium and zinc supplementation may help), sedation, and tremor.

Polycystic ovary syndrome (PCOS) association: valproate increases testosterone and LH levels in women and has been associated with PCOS development, particularly in younger women and adolescents. Female patients should be informed of this risk.

Pregnancy and Teratogenicity

Valproate carries the highest teratogenic risk of commonly used mood stabilizers. Neural tube defects occur in 1–2% of exposed pregnancies (vs. 0.05–0.1% baseline), and fetal valproate syndrome (growth restriction, facial dysmorphia, cognitive impairment, autism) occurs with higher-dose exposures. Current guidelines strongly recommend against valproate use in women of childbearing potential unless no other option is adequate and reliable contraception is in place. The European Medicines Agency has imposed mandatory educational measures given ongoing prescribing in this population.

Lamotrigine is mechanistically distinct from lithium and valproate: it works primarily through sodium channel blockade and glutamate modulation rather than direct GABA potentiation. Its clinical niche is maintenance treatment of bipolar depression — it is the agent with the strongest evidence for preventing depressive recurrences in bipolar I and II. It is not effective for acute mania and should not be used as monotherapy for acute manic episodes.

Clinical advantages: excellent cognitive profile (many patients report improved clarity compared to other mood stabilizers), weight-neutral, and no routine blood monitoring required.

The Rash Protocol: Never Rush the Titration

Lamotrigine requires a slow titration protocol — and this is non-negotiable. Starting at 25mg per day and increasing by no more than 25mg every two weeks is the standard protocol. Rushing the titration significantly increases the risk of Stevens-Johnson Syndrome (SJS), a rare but potentially fatal hypersensitivity reaction involving the skin and mucous membranes. Any rash while on lamotrigine requires stopping the medication and contacting a prescriber immediately. Most rashes on lamotrigine are benign — but the potentially serious ones look identical in early stages, so the protocol is to stop and evaluate every rash.

Critical Drug Interactions

• Valproate doubles lamotrigine levels: if valproate is added to lamotrigine (or vice versa), the lamotrigine dose must be halved. Failure to adjust doses dramatically increases rash risk.
• Carbamazepine halves lamotrigine levels: induction of hepatic enzymes reduces lamotrigine exposure.
• Pregnancy: lamotrigine levels drop 40–50% during pregnancy due to increased glucuronidation. Dose increases are routinely needed as pregnancy progresses; levels should be monitored and doses adjusted accordingly.

Several second-generation antipsychotics (SGAs) have FDA indications for bipolar disorder and function as mood stabilizers in clinical practice — though their mechanism (dopamine and serotonin receptor modulation) differs fundamentally from lithium and the anticonvulsants. The key agents:

• Quetiapine (Seroquel): FDA approved for acute mania, bipolar depression, and maintenance — one of the few agents with evidence across all phases. Commonly used as monotherapy or adjunct.
• Olanzapine/fluoxetine combination (Symbyax): FDA approved for bipolar depression. The only olanzapine-containing formulation with a bipolar depression indication.
• Aripiprazole (Abilify): FDA approved for acute mania and maintenance; partial dopamine agonist mechanism; generally weight-neutral relative to other SGAs.
• Lurasidone (Latuda): FDA approved for bipolar depression specifically; relatively favorable metabolic profile; requires administration with food (at least 350 calories).

The distinction between using an SGA as a mood stabilizer vs. an adjunct matters clinically. As mood stabilizers, these agents are used for ongoing maintenance treatment, not just acute episodes. The metabolic risks (weight gain, glucose dysregulation, dyslipidemia, prolactin elevation) are relevant to long-term use and should be monitored and discussed explicitly with patients.

If you are reading this guide to better understand your treatment plan, these related resources may also be useful:

• Managing Medication Side Effects — practical strategies for the most common side effects across mood stabilizers and other psychiatric medications
• Medication Tapering Guide — what you need to know before stopping or reducing any psychiatric medication